Generalizability of Progression Risk in the TN-10 Trial to a European Population With or Without a First-Degree Relative With Type 1 Diabetes.

Journal:

Diabetes Care

Published:

2025-10-22

DOI:

10.2337/dc25-1021

Affiliations:

7

Authors:

10

Go to article

Institutions	Authors	Share
Helmholtz Zentrum München - German Research Center for Environmental Health (HMGU), Germany	3.333333	0.33
Sanofi, France	3.000000	0.30
Thermo Fisher Scientific, Villebon sur Yvette, France	1.000000	0.10
TUM University Hospital Klinikum rechts der Isar (MRI), Germany	0.833333	0.08
German Center for Diabetes Research (DZD), Germany	0.833333	0.08
Evidera - UK, United Kingdom (UK)	0.500000	0.05
King's College London (KCL), United Kingdom (UK)	0.500000	0.05

Interested in Immunology?